MedElevator Войти в исследования
← Поиск публикаций

DOI 10.21037/jgo-20-610

Медицинская библиотека · Journal of gastrointestinal oncology · 2021

Molecular characterization of squamous cell carcinoma of the anal canal.

Armstrong Samantha A, Malley Rita, Wang Hongkun, Lenz Heinz-Josef, Arguello David, El-Deiry Wafik S, Xiu Joanne, Gatalica Zoran, Hwang Jimmy J, Philip Philip A, Shields Anthony F, Marshall John L, Salem Mohamed E, Weinberg Benjamin A

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Squamous cell carcinoma of the anal canal (SCCA) is an uncommon malignancy with limited therapeutic options. Nivolumab and pembrolizumab show promising results in patients with SCCA. Human papillomavirus (HPV)-negative tumors are frequently TP53-mutated (TP53-MT) and often resistant to therapy.

METHODS

We present a large molecularly-profiled cohort of SCCA, exploring the underlying biology of SCCA, differences between TP53-wild type (TP53-WT) and TP53-MT tumors, and differences between local and metastatic tumors. SCCA specimens (n=311) underwent multiplatform testing with immunohistochemistry (IHC), in situ hybridization (ISH) and next-generation sequencing (NGS). Tumor mutational burden (TMB) was calculated using only somatic nonsynonymous missense mutations. Chi-square testing was used for comparative analyses.

RESULTS

The most frequently mutated genes included PIK3CA (28.1%), KMT2D (19.5%), FBXW7 (12%), TP53 (12%) and PTEN (10.8%). The expression of PD-1 was seen in 68.8% and PD-L1 in 40.5% of tumors. High TMB was present in 6.7% of specimens. HER2 IHC was positive in 0.9%, amplification by chromogenic in situ hybridization (CISH) was seen 1.3%, and mutations in ERBB2 were present in 1.8% of tumors. The latter mutation has not been previously described in SCCA. When compared with TP53-WT tumors, TP53-MT tumors had higher rates of CDKN2A, EWSR1, JAK1, FGFR1 and BRAF mutations. PD-1 and PD-L1 expression were similar, and high TMB did not correlate with PD-1 (P=0.50) or PD-L1 (P=0.52) expression.

CONCLUSIONS

Molecular profiling differences between TP53-MT and TP53-WT SCCA indicate different carcinogenic pathways which may influence response to therapy. Low frequency mutations in several druggable genes may provide therapeutic opportunities for patients with SCCA.

Для цитирования: Armstrong Samantha A, Malley Rita, Wang Hongkun, Lenz Heinz-Josef, Arguello David, El-Deiry Wafik S, Xiu Joanne, Gatalica Zoran, Hwang Jimmy J, Philip Philip A, Shields Anthony F, Marshall John L, Salem Mohamed E, Weinberg Benjamin A. Molecular characterization of squamous cell carcinoma of the anal canal.. Journal of gastrointestinal oncology. 2021. DOI: 10.21037/jgo-20-610.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.